US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kalaris Therapeutics Inc.

9.05

+0.71008.51%

Post-market: 9.050.00000.00%17:23 EST

Volume:57.11K

Turnover:510.30K

Market Cap:169.26M

PE:-2.62

High:9.29

Open:8.35

Low:8.34

Close:8.34

52wk High:12.90

52wk Low:2.14

Shares:18.70M

Float Shares:4.31M

Volume Ratio:1.48

T/O Rate:1.33%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.4594

EPS(LYR):-10.4377

ROE:--

ROA:-63.50%

PB:4.04

PE(LYR):-0.87

Loading ...

Overview Company News Filings

Kalaris Therapeutics Unveils Phase 1 Data for TH103 in Neovascular AMD at Macula Society Meeting

Kalaris Therapeutics Initiated at Buy by Chardan Capital

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Posts Positive Results from Macular Degeneration Drug Trial

MT Newswires Live

BRIEF-Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103

Kalaris Therapeutics Reports Positive Initial Phase 1a Results for TH103 in Neovascular AMD

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-NaÏVe Neovascular Amd

THOMSON REUTERS

Kalaris Therapeutics Inc - TH103 Generally Well Tolerated, Supporting Further Dose Escalation

THOMSON REUTERS

Kalaris Therapeutics Inc - TH103 Showed Mean 10-Letter Gain in Visual Acuity at Month 1

THOMSON REUTERS

Kalaris Therapeutics Inc - Accelerating Enrollment in Phase 1B/2 Study; Data Expected 2H 2026

THOMSON REUTERS

Kalaris Therapeutics to Present at Noble Capital Markets Emerging Growth Equity Conference

Kalaris Therapeutics: Phase 1a Single Ascending Dose Trial Remains on Track for Initial Clinical Data to Be Reported by Year End

THOMSON REUTERS

Kalaris Therapeutics Inc - $77 Mln Cash as of Sept 30, to Fund Operations Into 2027

THOMSON REUTERS

Kalaris Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview

Kalaris Therapeutics Files Initial Beneficial Ownership Statement for CFO Matthew Gall

Kalaris Therapeutics Inc - Appoints Matthew Gall as Chief Financial Officer

THOMSON REUTERS

Press Release: Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Private equity firms in Kalaris Therapeutics, Inc. (NASDAQ:KLRS) are its biggest bettors, and their bets paid off as stock gained 24% last week

Simply Wall St.

Leerink Partners Remains a Buy on Kalaris Therapeutics (KLRS)

BRIEF-Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment Underway

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KLRS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KLRS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":9.05,"timestamp":1770670800000,"preClose":8.34,"halted":0,"volume":57113,"hourTrading":{"tag":"盘后","latestPrice":9.05,"preClose":9.05,"latestTime":"17:23 EST","volume":299,"amount":2706.13,"timestamp":1770675805078,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.08513189448441258,"floatShares":4309313,"shares":18702418,"eps":-3.459444,"marketStatus":"Closed","change":0.71,"latestTime":"02-09 16:00:00 EST","open":8.35,"high":9.29,"low":8.34,"amount":510302.2553,"amplitude":0.113909,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.459444,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":5,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":8.34,"preHourTrading":{"tag":"盘前","latestPrice":8.17,"preClose":8.34,"latestTime":"06:02 EST","volume":31,"amount":253.27,"timestamp":1770634940016,"change":-0.17,"changeRate":-0.020384,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":9.05,"preClose":9.05,"latestTime":"17:23 EST","volume":299,"amount":2706.13,"timestamp":1770675805078,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.47678},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","floatShares":4309313,"roa":"-63.50%","roe":"--","lyrEps":-10.437743,"volumeRatio":1.47678,"shares":18702418,"dividePrice":0,"high":9.29,"amplitude":0.113909,"preClose":8.34,"low":8.34,"week52Low":2.14,"pbRate":"4.04","week52High":12.9,"institutionHeld":0,"latestPrice":9.05,"eps":-3.459444,"divideRate":0,"volume":57113,"delay":0,"ttmEps":-3.459444,"open":8.35,"prevYearClose":8.44,"prevWeekClose":8.34,"prevMonthClose":8.88,"prevQuarterClose":8.44,"fiveDayClose":9.11,"twentyDayClose":9.78,"sixtyDayClose":5.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"KLRS","fiscalQuarterEnding":"2025/09","expectedEps":-0.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.64},{"market":"US","date":"2025-08-13","symbol":"KLRS","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.61},{"market":"US","date":"2025-05-14","symbol":"KLRS","fiscalQuarterEnding":"2025/03","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-2.52},{"market":"US","date":"2025-03-07","symbol":"KLRS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741323600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-01-16","symbol":"KLRS","defaultRemindTime":1737037800000,"type":"split","dateTimestamp":1737003600000,"forFactor":23,"toFactor":1,"ratio":23}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.3333,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":6,"updateTime":1766552400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRS","date":"2026-02-06","current":-2.616027,"percent":0.150685,"low":-3.513489,"twenty":-2.367922,"median":-1.114275,"eighty":-0.662351,"high":-0.558935,"avg":-1.507279,"sd":0.893964,"marketCap":156165190},"quantilePoints":[{"date":"2025-03-28","current":-2.436259,"twenty":-2.629862,"median":-2.463299,"eighty":-2.415709,"marketCap":168508741},{"date":"2025-04-04","current":-2.000923,"twenty":-2.457891,"median":-2.325397,"eighty":-2.168027,"marketCap":138397856},{"date":"2025-04-11","current":-1.976588,"twenty":-2.405434,"median":-2.167216,"eighty":-1.951712,"marketCap":136714639},{"date":"2025-04-17","current":-1.811647,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"marketCap":125306167},{"date":"2025-04-25","current":-1.762976,"twenty":-2.268073,"median":-1.954956,"eighty":-1.818136,"marketCap":121939732},{"date":"2025-05-02","current":-1.581811,"twenty":-2.177762,"median":-1.903581,"eighty":-1.797045,"marketCap":109409116},{"date":"2025-05-09","current":-1.041021,"twenty":-2.168027,"median":-1.865726,"eighty":-1.715927,"marketCap":72004290},{"date":"2025-05-16","current":-0.871644,"twenty":-2.131794,"median":-1.821111,"eighty":-1.36225,"marketCap":66206559},{"date":"2025-05-23","current":-0.696822,"twenty":-2.051217,"median":-1.811647,"eighty":-0.924751,"marketCap":52927842},{"date":"2025-05-30","current":-0.728832,"twenty":-1.996056,"median":-1.784607,"eighty":-0.873072,"marketCap":55359157},{"date":"2025-06-06","current":-0.765766,"twenty":-1.972262,"median":-1.721064,"eighty":-0.77266,"marketCap":58164519},{"date":"2025-06-13","current":-0.679587,"twenty":-1.946844,"median":-1.576403,"eighty":-0.758379,"marketCap":51618673},{"date":"2025-06-20","current":-0.632803,"twenty":-1.914397,"median":-1.295192,"eighty":-0.733756,"marketCap":48065214},{"date":"2025-06-27","current":-0.630341,"twenty":-1.911693,"median":-0.990998,"eighty":-0.714058,"marketCap":47878190},{"date":"2025-07-03","current":-0.615567,"twenty":-1.898714,"median":-0.913935,"eighty":-0.685496,"marketCap":46756045},{"date":"2025-07-11","current":-0.615567,"twenty":-1.891143,"median":-0.871644,"eighty":-0.649054,"marketCap":46756045},{"date":"2025-07-18","current":-0.595869,"twenty":-1.870593,"median":-0.816242,"eighty":-0.639205,"marketCap":45259851},{"date":"2025-07-25","current":-0.699285,"twenty":-1.8614,"median":-0.765766,"eighty":-0.634773,"marketCap":53114867},{"date":"2025-08-01","current":-0.659888,"twenty":-1.83436,"median":-0.758379,"eighty":-0.635266,"marketCap":50122480},{"date":"2025-08-08","current":-0.667275,"twenty":-1.817055,"median":-0.738681,"eighty":-0.635266,"marketCap":50683552},{"date":"2025-08-15","current":-0.558935,"twenty":-1.812188,"median":-0.724523,"eighty":-0.632803,"marketCap":42454488},{"date":"2025-08-22","current":-0.563436,"twenty":-1.811647,"median":-0.714058,"eighty":-0.627879,"marketCap":46007948},{"date":"2025-08-29","current":-0.815379,"twenty":-1.792178,"median":-0.714058,"eighty":-0.615567,"marketCap":66580608},{"date":"2025-09-05","current":-1.067322,"twenty":-1.785689,"median":-0.715289,"eighty":-0.622954,"marketCap":87153267},{"date":"2025-09-12","current":-0.980287,"twenty":-1.771628,"median":-0.728832,"eighty":-0.627879,"marketCap":80046349},{"date":"2025-09-19","current":-1.005482,"twenty":-1.753242,"median":-0.746068,"eighty":-0.629356,"marketCap":82103615},{"date":"2025-09-26","current":-1.092517,"twenty":-1.715927,"median":-0.758379,"eighty":-0.630341,"marketCap":89210533},{"date":"2025-10-03","current":-1.623887,"twenty":-1.652483,"median":-0.783002,"eighty":-0.631818,"marketCap":132600143},{"date":"2025-10-10","current":-1.059306,"twenty":-1.715927,"median":-0.815379,"eighty":-0.632803,"marketCap":86498683},{"date":"2025-10-17","current":-1.097097,"twenty":-1.652483,"median":-0.853303,"eighty":-0.634281,"marketCap":89584582},{"date":"2025-10-24","current":-1.120001,"twenty":-1.598641,"median":-0.878784,"eighty":-0.635266,"marketCap":91454824},{"date":"2025-10-31","current":-1.085645,"twenty":-1.578566,"median":-0.913935,"eighty":-0.635266,"marketCap":88649461},{"date":"2025-11-07","current":-1.083355,"twenty":-1.543053,"median":-0.93448,"eighty":-0.63822,"marketCap":88462437},{"date":"2025-11-14","current":-1.220778,"twenty":-1.513949,"median":-0.991739,"eighty":-0.641667,"marketCap":99683887},{"date":"2025-11-21","current":-2.326591,"twenty":-1.652483,"median":-1.007772,"eighty":-0.642652,"marketCap":129046684},{"date":"2025-11-28","current":-2.104047,"twenty":-1.7661,"median":-1.019224,"eighty":-0.643637,"marketCap":116703088},{"date":"2025-12-05","current":-1.996147,"twenty":-1.811647,"median":-1.04043,"eighty":-0.647085,"marketCap":110718314},{"date":"2025-12-12","current":-2.808768,"twenty":-1.83375,"median":-1.046709,"eighty":-0.650039,"marketCap":155791141},{"date":"2025-12-19","current":-3.513489,"twenty":-1.853956,"median":-1.059878,"eighty":-0.652009,"marketCap":194879195},{"date":"2025-12-26","current":-3.230252,"twenty":-1.885652,"median":-1.065031,"eighty":-0.655456,"marketCap":179169164},{"date":"2026-01-02","current":-2.845859,"twenty":-1.914397,"median":-1.075338,"eighty":-0.657426,"marketCap":157848407},{"date":"2026-01-09","current":-2.785165,"twenty":-1.996147,"median":-1.083355,"eighty":-0.657426,"marketCap":154481972},{"date":"2026-01-16","current":-2.987477,"twenty":-2.104047,"median":-1.089081,"eighty":-0.657426,"marketCap":165703423},{"date":"2026-01-23","current":-3.29769,"twenty":-2.164782,"median":-1.092517,"eighty":-0.659396,"marketCap":182909648},{"date":"2026-01-30","current":-3.102121,"twenty":-2.196152,"median":-1.097097,"eighty":-0.661858,"marketCap":172062245},{"date":"2026-02-06","current":-2.815512,"twenty":-2.367922,"median":-1.114275,"eighty":-0.662351,"marketCap":156165190}],"updateTime":1770675518760},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607740698","title":"Kalaris Therapeutics Unveils Phase 1 Data for TH103 in Neovascular AMD at Macula Society Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2607740698","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607740698?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:05","pubTimestamp":1769634334,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc. announced that clinical data from its Phase 1 study of TH103, a novel dual-targeting VEGF and HSPG inhibitor, will be presented at the 49th Annual Meeting of the Macula Society. The presentation is scheduled for February 26, 2026, in San Diego, California, and will cover safety, tolerability, pharmacokinetics, and early efficacy outcomes following intravitreal administration of TH103 in patients with treatment-naive neovascular age-related macular degeneration. The results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 28, 2026, and is solely responsible for the i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL5vPbtk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","BK4585","SG9999014021.USD","LU2210149790.SGD","BK4112","SG9999014013.SGD","KLRS","BK4588"],"gpt_icon":0},{"id":"2593589490","title":"Kalaris Therapeutics Initiated at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2593589490","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593589490?lang=en_us&edition=fundamental","pubTime":"2025-12-23 20:52","pubTimestamp":1766494320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KLRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2025 07:52 ET (12:52 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","KLRS","BK4139","BK4007"],"gpt_icon":0},{"id":"2592949765","title":"Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592949765","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592949765?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:59","pubTimestamp":1766012340,"startTime":"0","endTime":"0","summary":"BERKELEY HEIGHTS, N.J., Dec.  17, 2025  (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercia","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3207378/0/en/Kalaris-Therapeutics-Announces-Oversubscribed-50-0-Million-Private-Placement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139","BK4539","BK4007","LENZ"],"gpt_icon":0},{"id":"2592694964","title":"Kalaris Posts Positive Results from Macular Degeneration Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592694964","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592694964?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:50","pubTimestamp":1766011814,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics  reported late Wednesday positive initial data from its Phase 1a trial of its investigational drug for treating naive neovascular AMD patients.The single ascending dose  trial showed the drug candidate, TH103, had clinically meaningful improvements in vision and retinal anatomy.The trial also indicated early signs of potential for extended treatment durability.The company expects to share preliminary data from the ongoing Phase 1b/2 study in the second half of 2026Shares were down nearly 15% in recent after-hours activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2592943616","title":"BRIEF-Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943616","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943616?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:04","pubTimestamp":1766005444,"startTime":"0","endTime":"0","summary":"BRIEF-Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103Dec 17 (Reuters) - Kalaris Therapeutics Inc KLRS.O:KALARIS THERAPEUTICS REPORTS POSITIVE INITIAL PHASE 1A DATA FOR TH103 IN T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2592943510","title":"Kalaris Therapeutics Reports Positive Initial Phase 1a Results for TH103 in Neovascular AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943510","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943510?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:01","pubTimestamp":1766005274,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc. announced positive initial results from its Phase 1a single ascending dose trial of TH103, a fully humanized recombinant fusion protein targeting VEGF, in treatment-nave patients with neovascular age-related macular degeneration . The data showed a mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at one month following a single injection. TH103 was generally well tolerated, and pharmacokinetic analysis indicated a 27 to 51-fold lower plasma Cmax compared to current leading agents, suggesting increased intraocular retention. The results were presented during a live webcast and conference call on December 17, 2025. Kalaris is continuing enrollment in an ongoing Phase 1b/2 multi-ascending dose study, with preliminary efficacy and safety data expected in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely inform","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL89hgYB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","LU2210149790.SGD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","KLRS","BK4139","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2592943505","title":"Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-NaÏVe Neovascular Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943505","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943505?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:01","pubTimestamp":1766005271,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2592943504","title":"Kalaris Therapeutics Inc - TH103 Generally Well Tolerated, Supporting Further Dose Escalation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943504?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:01","pubTimestamp":1766005271,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"gpt_icon":0},{"id":"2592656943","title":"Kalaris Therapeutics Inc - TH103 Showed Mean 10-Letter Gain in Visual Acuity at Month 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2592656943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592656943?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:01","pubTimestamp":1766005271,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18T:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2592436359","title":"Kalaris Therapeutics Inc - Accelerating Enrollment in Phase 1B/2 Study; Data Expected 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592436359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592436359?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:01","pubTimestamp":1766005271,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18T:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2585462579","title":"Kalaris Therapeutics to Present at Noble Capital Markets Emerging Growth Equity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462579?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:01","pubTimestamp":1763989287,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc. will present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference on Wednesday, December 3, 2025. Chief Medical Officer Matthew Feinsod is scheduled to speak from 11:30 to 11:55 am ET at Florida Atlantic University in Boca Raton, FL. Kalaris management will also be available for one-on-one meetings during the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via Newsfile  on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLJBmFg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2582937185","title":"Kalaris Therapeutics: Phase 1a Single Ascending Dose Trial Remains on Track for Initial Clinical Data to Be Reported by Year End","url":"https://stock-news.laohu8.com/highlight/detail?id=2582937185","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582937185?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952408,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA6NQDZB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2582893371","title":"Kalaris Therapeutics Inc - $77 Mln Cash as of Sept 30, to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2582893371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582893371?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:00","pubTimestamp":1762952408,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA6NQDZB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2581783277","title":"Kalaris Therapeutics Inc  expected to post a loss of 65 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581783277","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581783277?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:50","pubTimestamp":1762555806,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc  expected to post a loss of65cents a share - Earnings Preview Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to  report resultson November 10 (estimated) for the period e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ31X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"gpt_icon":0},{"id":"2580229782","title":"Kalaris Therapeutics Files Initial Beneficial Ownership Statement for CFO Matthew Gall","url":"https://stock-news.laohu8.com/highlight/detail?id=2580229782","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580229782?lang=en_us&edition=fundamental","pubTime":"2025-11-04 06:23","pubTimestamp":1762208618,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Matthew Gall, Chief Financial Officer of Kalaris Therapeutics, as the reporting beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDLb7K4ym:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2580902742","title":"Kalaris Therapeutics Inc - Appoints Matthew Gall as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2580902742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580902742?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:30","pubTimestamp":1762173014,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nFWN3WF057:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"2580290754","title":"Press Release: Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2580290754","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580290754?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:30","pubTimestamp":1762173000,"startTime":"0","endTime":"0","summary":"Highly experienced biopharma financial officer joins leadership team. CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in treatment nave nAMD patients. PALO ALTO, Calif., Nov. 03, 2025  -- Kalaris Therapeutics , a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew Gall, MBA, as Chief Financial Officer.\"I am delighted to welcome Matthew to our team,\" said Andrew Oxtoby, President and Chief Executive Officer of Kalaris Therapeutics. \"Matt is an experienced chief financial officer and strategic leader with a track record of successfully scaling up biopharmaceutical companies, directing capital raising rounds, and negotiating highly beneficial partnership deals. He will be a valuable addition to our leadership team and will support our company's evolution as we advance our clinical develop","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TISI","BK4139","BK4120","KLRS"],"gpt_icon":0},{"id":"2570184060","title":"Private equity firms in Kalaris Therapeutics, Inc. (NASDAQ:KLRS) are its biggest bettors, and their bets paid off as stock gained 24% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2570184060","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570184060?lang=en_us&edition=fundamental","pubTime":"2025-09-28 20:23","pubTimestamp":1759062236,"startTime":"0","endTime":"0","summary":"Key Insights Kalaris Therapeutics' significant private equity firms ownership suggests that the key decisions are...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klrs/kalaris-therapeutics/news/private-equity-firms-in-kalaris-therapeutics-inc-nasdaqklrs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-klrs/kalaris-therapeutics/news/private-equity-firms-in-kalaris-therapeutics-inc-nasdaqklrs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["USJW.SI",".IXIC","QLD","PSQ","MNQmain","QID","KLRS","BK4139","NQmain","NVIW.SI","TSYW.SI","USAW.SI","SQQQ","TQQQ"],"gpt_icon":1},{"id":"2568495340","title":"Leerink Partners Remains a Buy on Kalaris Therapeutics (KLRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2568495340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568495340?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:45","pubTimestamp":1758109514,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Marc Goodman from Leerink Partners reiterated a Buy rating on Kalaris Therapeutics, with a price target of $20.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-remains-a-buy-on-kalaris-therapeutics-klrs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-remains-a-buy-on-kalaris-therapeutics-klrs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KLRS"],"gpt_icon":0},{"id":"2567119024","title":"BRIEF-Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2567119024","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567119024?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:08","pubTimestamp":1757938092,"startTime":"0","endTime":"0","summary":"BRIEF-Kalaris Begins Phase 1b/2 Study Of TH103 For Neovascular AMD With Multiple Ascending Dose Enrollment UnderwaySept 15 (Reuters) - Kalaris Therapeutics Inc KLRS.O:KALARIS THERAPEUTICS NOW ENROLLIN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nTUAFMSSF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}